• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

The millennial generation is split in 2: an older crowd with boomer-style comfort, a younger set going 'back to the early 1900s'

2

Trump pulls back after Iran crosses his red line as U.S. military breaks two-week streak of airstrikes amid talks for potential Hormuz deal

3

'The demographic dividend of the last 40 years is ending': J.P. Morgan says the world is running out of the two things that kept interest rates down

1

The millennial generation is split in 2: an older crowd with boomer-style comfort, a younger set going 'back to the early 1900s'

2

Trump pulls back after Iran crosses his red line as U.S. military breaks two-week streak of airstrikes amid talks for potential Hormuz deal

3

'The demographic dividend of the last 40 years is ending': J.P. Morgan says the world is running out of the two things that kept interest rates down
HealthCOVID-19 vaccines

RFK Jr. has accused the FDA of suppressing hydroxychloroquine. Now, the study that suggested its use in COVID is retracted.

Beth Greenfield
By
Beth Greenfield
Beth Greenfield
Senior Reporter, Fortune Well
Down Arrow Button Icon
Beth Greenfield
By
Beth Greenfield
Beth Greenfield
Senior Reporter, Fortune Well
Down Arrow Button Icon
December 18, 2024, 2:08 PM ET
Closeup of a bottle of hydroxychloroquine and scattered pills
The study that set of a wave of excitement over hydroxychloroquine and COVID has been retracted. GEORGE FREY/AFP via Getty Images
Add Fortune on Google for similar content.

A study that prompted hope for a COVID-19 treatment in the early days of the pandemic has now been formally retracted by the scientific journal that published it.

Recommended Video

Hydroxychloroquine, an antimalarial drug also approved for use in some autoimmune diseases, was first introduced to the world as a potential cure through a March 2020 study of 36 patients with COVID in the International Journal of Antimicrobial Agents. Elsevier, which owns the journal, issued its formal retraction on Tuesday.

“Concerns have been raised regarding this article, the substance of which relate to the articles’ adherence to Elsevier’s publishing ethics policies and the appropriate conduct of research involving human participants, as well as concerns raised by three of the authors themselves regarding the article’s methodology and conclusions,” the lengthy retraction statement noted, in part.

It is the most highest-cited paper on COVID-19 to be retracted, and the second-most-cited retracted paper of any kind, according to the journal Nature.

The study’s initial publication set off a frenzy of excitement over the drug’s potential. The U.S. Food and Drug Administration issued an Emergency Use Authorization to allow it to be stockpiled and distributed to certain patients hospitalized with COVID. President Donald Trump announced that he was taking it prophylactically, and prescriptions for the drug increased from 1,143 in February 2020 to 75,569 in March 2020, according to the Centers for Disease Control and Prevention.

Yale School of Public Health professor of epidemiology Harvey Risch said in July 2020 he believed that by not approving the drug for COVID use, “tens of thousands of patients with COVID-19 are dying unnecessarily.”

And Robert F. Kennedy Jr., Trump’s pick to head the Department of Health and Human Services, suggested hydroxychloroquine’s use for COVID was being “censored and politicized” in a July 2020 story on his Children’s Health Defense website. “For the biopharma companies poised to profit from new drugs and Covid-19 vaccines—including the alarming Moderna vaccine co-developed by NIAID—it is not an attractive option to keep older drugs that have outlived their patent terms in the running,” the story noted.

The study’s retraction puts an end to a long line of criticism that started almost immediately after its publication, including over its unusually short peer-review time and small sample size.

Elsevier said that other problems with the data included that six patients with results that would’ve changed the study’s positive conclusions were eliminated from the study after it began—something pointed out at the time by Dutch microbiologist Elisabeth Bik, who posted on X on Tuesday that the study was “finally” retracted. Elsevier also could not establish whether the patients had given fully informed consent to be treated with the antibiotic azithromycin, which was part of the study.

Lead author Didier Raoult, a French virologist who founded and directed the research hospital known as the Institut Hospitalo-Universitaire Méditerranée Infection, or IHU, was a controversial figure; 28 of his co-authored studies have now been retracted, according to Science. He faced a disciplinary hearing over recommending hydroxychloroquine for COVID, and was forced to step down from the IHU. He has also been dismissive of climate change, fear of epidemics, and Darwinian evolution.

Hydroxychloroquine has also been linked to serious side effects, including cardiac arrest, heart rhythm issues, liver failure, and kidney disorders, as noted by a 2020 FDA warning about the drug’s use for COVID treatment outside of a hospital setting.

“A dark page in COVID-19 research finally turned,” noted a statement issued this week by the French Society of Pharmacology and Therapeutics. “This highly controversial study was the cornerstone of a global scandal. The promotion of its results led to the overprescription of hydroxychloroquine to millions of patients, resulting in unnecessary risk-taking for millions of people and potentially thousands of avoidable deaths. It also resulted in a massive waste of resources and the proliferation of hundreds of useless studies, to the detriment of research into truly effective treatments.”

More on COVID:

  • Got COVID? Here are the new 2024 isolation guidelines
  • 54 million COVID cases went unreported in 2022, study says. Here’s how to make your at-home test count
  • The return-to-office wars have diminished workplace well-being—especially for these groups
Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up for free today.
About the Author
Beth Greenfield
By Beth GreenfieldSenior Reporter, Fortune Well

Beth Greenfield is a New York City-based health and wellness reporter on the Fortune Well team covering life, health, nutrition, fitness, family, and mind.

See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month
SuccessMarketing
A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month
By Sydney LakeJuly 25, 2026
1 day ago
Roderick Wong, MD is Managing Partner and Chief Investment Officer of RTW Investments
Commentary250 Years of Innovation
When 10,000 doctors stood up and cheered for a cancer drug — America’s innovation machine made it possible
By Roderick WongJuly 25, 2026
1 day ago
What it’s like to be a founder of the most high-stakes startup ever, OpenAI
AIOpenAI
What it’s like to be a founder of the most high-stakes startup ever, OpenAI
By Alyson ShontellJuly 25, 2026
1 day ago
Photo of RFK Jr.
HealthFDA
RFK Jr.’s peptide push narrowly gains backing from FDA advisers despite objections from scientists
By The Associated Press and Matthew PerroneJuly 24, 2026
2 days ago
PartiQular as best resveratrol supplement
HealthDietary Supplements
The Best Resveratrol Supplements (2026): Expert Reviewed
By Christina SnyderJuly 24, 2026
2 days ago
Sunlight Sauna Review
HealthDietary Supplements
Sunlighten Sauna Review (2026): Features, Cost, and Our Take
By Emily PharesJuly 24, 2026
2 days ago

Most Popular

The millennial generation is split in 2: an older crowd with boomer-style comfort, a younger set going 'back to the early 1900s'
Real Estate
The millennial generation is split in 2: an older crowd with boomer-style comfort, a younger set going 'back to the early 1900s'
By Nick LichtenbergJuly 25, 2026
1 day ago
Trump pulls back after Iran crosses his red line as U.S. military breaks two-week streak of airstrikes amid talks for potential Hormuz deal
Middle East
Trump pulls back after Iran crosses his red line as U.S. military breaks two-week streak of airstrikes amid talks for potential Hormuz deal
By Jason MaJuly 25, 2026
18 hours ago
'The demographic dividend of the last 40 years is ending': J.P. Morgan says the world is running out of the two things that kept interest rates down
Economy
'The demographic dividend of the last 40 years is ending': J.P. Morgan says the world is running out of the two things that kept interest rates down
By Eleanor PringleJuly 24, 2026
2 days ago
An 11-year-old is cleaning his neighbors' trash cans for $10 each—he now has 100K followers as teens face the worst summer job market since 1948
Success
An 11-year-old is cleaning his neighbors' trash cans for $10 each—he now has 100K followers as teens face the worst summer job market since 1948
By Orianna Rosa RoyleJuly 25, 2026
1 day ago
Startups are installing tiny data centers in people’s homes to reduce strain on the beleaguered electrical grid
Environment
Startups are installing tiny data centers in people’s homes to reduce strain on the beleaguered electrical grid
By Sasha RogelbergJuly 25, 2026
1 day ago
A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month
Success
A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month
By Sydney LakeJuly 25, 2026
1 day ago